RAS activating mutations occur in 30 % of all cancers, including a high prevalence in melanoma (15–25 %) [3, 5], with KRAS mutations more common in adenocarcinomas and solid tumors and NRAS mutations more common in leukemia, thyroid carcinoma, and malignant melanoma [6]. This evidence concerns the gene KRAS and cancer.